Abel Costa, MD (@anetoc) header
Abel Costa, MD (@anetoc) profile picture

Hematologist. Tweets are my own.

São Paulo, Brasil
Joined July 2010
Photo by Abel Costa, MD (@anetoc)Photo by Abel Costa, MD (@anetoc)Photo by Abel Costa, MD (@anetoc)Photo by Abel Costa, MD (@anetoc)Photo by Abel Costa, MD (@anetoc)Photo by Abel Costa, MD (@anetoc)Photo by Abel Costa, MD (@anetoc)Photo by Abel Costa, MD (@anetoc)Photo by Abel Costa, MD (@anetoc)Photo by Abel Costa, MD (@anetoc)
Truly grateful and proud to be part of a defining moment at #ASH2025. Contributing as an author to the EPCORE FL-1 trial — with simultaneous publication in @TheLancet and global regulatory impact — was a very special milestone in my academic journey. 🧵👇 – at Orlando, FL
11
12
653
In his opinion, HD Mtx remains SoC in testicular lymphoma. I agree 100%. Let the fight begin!
I had the opportunity to share a session on DLBCL with Dr. Vitolo. A true honor. And I had the opportunity to ask him about CNS prophylaxis in testicular lymphoma!
2
1
12
2,092
Our new review on AI in lymphoma diagnosis is out. A realistic look at how AI can support — not replace — clinical practice. Grateful to Marianne for the invitation and collaboration. 🔗 Link: rdcu.be/eWYH5 – at Brazil
1
103
Abel Costa, MD retweeted
EPCORE FL-1 Trial Shows Promising Results for Follicular Lymphoma - @anetoc oncodaily.com/voices/abel-co… #Cancer #OncoDaily #Oncology #MedEd #MedTwitter #MedX #MedOnc @CancerWorldmag
1
3
146
#ASH2025 was a meaningful milestone in my academic journey. Being an author on 4 oral presentations and 3 posters highlights the strength of collaborative clinical research and team science. Grateful to my mentor Eduardo Rego and the IDOR research team. – at Orlando, FL
2
197
One of the moments I was most proud of at #ASH2025 was seeing Luiza Lapolla present data from the Brazilian AML Registry, highlighting how social determinants shape AML outcomes using real-world national data. @abhhoficial – at Orlando, FL
4
211
Glad to contribute as an author to an oral presentation at #ASH2025 on golca ± rituxi in R/R FL. High ORR, durable responses, and manageable toxicity, even in heavily pretreated patients, supporting the role of targeted combinations in later lines. – at Orlando, FL
76
Grateful to contribute as an author to the TRAVERSE phase 2 study presented at #ASH2025. A chemotherapy-free triplet regimen, AVR in treatment-naïve MCL, showed deep responses and high MRD negativity, even in biologically high-risk subgroups. – at Orlando, FL
3
268
Taken together, EPCORE FL-1 shows that epcoritamab + R² achieves deep and durable responses, delays the need for subsequent therapy, and maintains a predictable, manageable safety profile, supporting its role as a new standard of care. – at Orlando, FL
1
86
🇧🇷 Proud to represent Brazil in this milestone and to be part of a global study with strong participation from Brazilian centers, contributing to a change in standard of care. – at Orlando, FL
34
Why this matters: ✔️First bispecific antibody approved in combination for FL ✔️Fixed-duration, chemotherapy-free regimen ✔️Immediate impact on treatment sequencing and clinical practice – at Orlando, FL
34
Safety profile was manageable and predictable, with no new safety signals: • CRS mostly grade 1–2; no grade ≥3 CRS • No tx discontinuations due to CRS • Neutropenia and infections were manageable • >90% relative dose intensity maintained Compatible with outpatient delivery. – at Orlando, FL
34
Despite still maturing follow-up, EPCORE FL-1 shows a statistically significant early OS signal, with separation of the curves and an HR of 0.38, favoring epcoritamab + R². – at Orlando, FL
78
Beyond PFS, EPCORE FL-1 showed a meaningful improvement in time to next treatment, reinforcing the durability and real-world relevance of responses. – at Orlando, FL
40
Key efficacy results: • ORR: 95.7% vs 81.0% • CR: 83% vs 50% • 79% reduction in risk of progression or death (HR 0.21) Benefit consistent across prespecified subgroups. – at Orlando, FL
46
EPCORE FL-1 design: • Phase 3, global, randomized • Epcoritamab + R² vs R² • R/R FL after ≥1 prior line • Dual primary endpoints: ORR and PFS – at Orlando, FL
84
Follicular lymphoma remains a chronic disease for most patients, with diminishing benefit after each line of therapy. EPCORE FL-1 addressed a critical unmet need: a fixed-duration, chemo-free strategy capable of delivering deep and durable remissions. – at Orlando, FL
2
69